|
1.
|
|
12 p, 801.4 KB |
Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid
/
Boström, Gustaf (Department of Public Health and Caring Sciences. Geriatrics. Uppsala University) ;
Freyhult, Eva (Department of Medical Sciences. Science for Life Laboratory. National Bioinformatics Infrastructure Sweden. Uppsala University) ;
Virhammar, Johan (Department of Neuroscience. Neurology. Uppsala University Hospital) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Tumani, Hayrettin (Department of Neurology. Ulm University Hospital) ;
Otto, Markus (Department of Neurology. Ulm University Hospital) ;
Brundin, Rose-Marie (Department of Public Health and Caring Sciences. Geriatrics. Uppsala University) ;
Kilander, Lena (Department of Public Health and Caring Sciences. Geriatrics. Uppsala University) ;
Löwenmark, Malin (Department of Public Health and Caring Sciences. Geriatrics. Uppsala University) ;
Giedraitis, Vilmantas (Department of Public Health and Caring Sciences. Geriatrics. Uppsala University) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Von Arnim, Christine A.F. (Department of Geriatric Medicine. University Medical Center Göttingen. Georg-August-University) ;
Kultima, Kim (Department of Medical Sciences. Clinical Chemistry. Uppsala University) ;
Ingelsson, Martin (Department of Public Health and Caring Sciences. Geriatrics. Uppsala University)
Background: Neuroinflammatory processes are common in neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal dementia (FTD), but current knowledge is limited as to whether cerebrospinal fluid (CSF) levels of neuroinflammatory proteins are altered in these diseases. [...]
2021 -  10.3233/jad-201565
Journal of Alzheimer's disease, Vol. 81 Núm. 2 (2021) , p. 629-640
|
|
|
2.
|
|
12 p, 2.0 MB |
A multicentre validation study of the diagnostic value of plasma neurofilament light
/
Ashton, Nicholas J. (NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation) ;
Janelidze, Shorena (Clinical Memory Research Unit. Department of Clinical Sciences Malmö. Lund University) ;
Al Khleifat, Ahmad (Department of Basic and Clinical Neuroscience. Maurice Wohl Clinical Neuroscience Institute. King's College London) ;
Leuzy, Antoine (Clinical Memory Research Unit. Department of Clinical Sciences Malmö. Lund University) ;
van der Ende, Emma L. (Alzheimer Center Rotterdam and Dept. of Neurology. Erasmus University Medical Center) ;
Karikari, Thomas K (Department of Psychiatry and Neurochemistry. Institute of Neuroscience & Physiology. The Sahlgrenska Academy at the University of Gothenburg) ;
Benedet, AndreaL. (Montreal Neurological Institute) ;
Pascoal, Tharick A. (Montreal Neurological Institute) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Parnetti, Lucilla (Laboratory of Clinical Neurochemistry. Neurology Clinic. University of Perugia) ;
Galimberti, Daniela (University of Milan) ;
Bonanni, Laura (Department of Neuroscience. Imaging and Clinical Sciences. University G.d'Annunzio of Chieti-Pescara) ;
Pilotto, Andrea (Parkinson's Disease Rehabilitation Centre. FERB ONLUS) ;
Padovani, Alessandro (Neurology Unit. Department of Clinical and Experimental Sciences. University of Brescia) ;
Lycke, Jan (Sahlgrenska University Hospital (Suècia)) ;
Novakova, Lenka (Sahlgrenska University Hospital (Suècia)) ;
Axelsson, Markus (Sahlgrenska University Hospital (Suècia)) ;
Velayudhan, Latha (Department of Health Sciences. University of Leicester) ;
Rabinovici, Gil D. (Department of Radiology & Biomedical Imaging. University of California) ;
Miller, Bruce (Department of Neurology. University of California San Francisco. Memory and Aging Center) ;
Pariante, Carmine (Stress. Psychiatry and Immunology Lab & Perinatal Psychiatry. Maurice Wohl Clinical Neuroscience Institute. King's College London) ;
Nikkheslat, Naghmeh (Stress. Psychiatry and Immunology Lab & Perinatal Psychiatry. Maurice Wohl Clinical Neuroscience Institute. King's College London) ;
Resnick, Susan M. (Brain Aging and Behavior Section. Laboratory of Behavioral Neuroscience. National Institute on Aging. National Institutes of Health) ;
Thambisetty, Madhav (Clinical and Translational Neuroscience Section. Laboratory of Behavioral Neuroscience. National Institute on Aging. National Institutes of Health) ;
Schöll, Michael (Department of Neurodegenerative Disease. Queen Square Institute of Neurology. University College London) ;
Fernández-Eulate, Gorka (Department of Neurology. Donostia University Hospital. Osakidetza) ;
Gil-Bea, Francisco J. (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
López de Munain, Adolfo (Universidad del País Vasco. Departamento de Neurociencias) ;
Al-Chalabi, Ammar (King's College Hospital. Department of Neurology) ;
Rosa-Neto, Pedro (Montreal Neurological Institute) ;
Strydom, Andre (London Down Syndrome Consortium (LonDowns)) ;
Svenningsson, Per (Karolinska Institutet (Estocolm, Suècia). Department of Clinical Neuroscience) ;
Stomrud, Erik (Skåne University Hospital (Suècia)) ;
Santillo, Alexander (Lund University. Department of Clinical Sciences Malmö) ;
Aarsland, Dag (Stavanger University Hospital) ;
van Swieten, John C. (Erasmus University Medical Center) ;
Palmqvist, Sebastian (Lund University. Skåne University Hospital) ;
Zetterberg, Henrik (University College London. UK Dementia Research Institute) ;
Blennow, Kaj (Sahlgrenska University Hospital (Suècia)) ;
Hye, Abdul (Stavanger University Hospital) ;
Hansson, Oskar (Skåne University Hospital (Suècia))
Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a marker of neurodegeneration in 13 neurodegenerative disorders, Down syndrome, depression and cognitively unimpaired controls from two multicenter cohorts: King's College London (n = 805) and the Swedish BioFINDER study (n = 1,464). [...]
2021 - 10.1038/s41467-021-23620-z
Nature communications, Vol. 12 Núm. 1 (january 2021) , p. 3400
|
|
|
3.
|
|
8 p, 1.7 MB |
Plasma Proteomic Biomarkers Relating to Alzheimer's Disease : A Meta-Analysis Based on Our Own Studies
/
Shi, L. (Department of Psychiatry. University of Oxford) ;
Buckley, Noel J (Department of Psychiatry. University of Oxford) ;
Bos, Isabelle (Alzheimer Center. VU University Medical Center) ;
Engelborghs, S. (Department of Neurology. Universitair Ziekenhuis Brussel. Center for Neurociences (C4N). Vrije Universiteit Brussel) ;
Sleegers, K. (Institute Born-Bunge. Department of Biomedical Sciences. University of Antwerp) ;
Frisoni, G.B. (Department of Psychiatry. University of Geneva) ;
Wallin, A. (Institute of Neuroscience and Physiology. Department of Psychiatry and Neurochemistry. The Sahlgrenska Academy at the University of Gothenburg) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Popp, J. (Geriatric Psychiatry. Department of Mental Health and Psychiatry. Geneva University Hospitals) ;
Martinez-Lage, P. (CITA-Alzheimer Foundation) ;
Legido-Quigley, C. (The Systems Medicine Group. Steno Diabetes Center) ;
Barkhof, F. (UCL Institutes of Neurology and Healthcare Engineering) ;
Zetterberg, Henrik (Department of Neurodegenerative Disease. UCL Institute of Neurology) ;
Visser, P.J. (Alzheimer Center. VU University Medical Center) ;
Bertram, Lars (Department of Psychology. University of Oslo) ;
Lovestone, S. ;
Nevado-Holgado, Alejo (Department of Psychiatry. University of Oxford)
Background and Objective: Plasma biomarkers for the diagnosis and stratification of Alzheimer's disease (AD) are intensively sought. However, no plasma markers are well established so far for AD diagnosis. [...]
2021 - 10.3389/fnagi.2021.712545
Frontiers in aging neuroscience, Vol. 13 (July 2021) , p. 712545
|
|
|
4.
|
|
5 p, 501.6 KB |
CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia
/
van der Ende, Emma L (Alzheimer Center Rotterdam and Dept. of Neurology. Erasmus University Medical Center) ;
Morenas-Rodriguez, E. (Metabolic Biochemistry. Biomedical Center (BMC). Faculty of Medicine. Ludwig-Maximillians-Universität München) ;
McMillan, C. (Dept. of Neurology. Penn Frontotemporal Degeneration Center. University of Pennsylvania Perelman School of Medicine) ;
Grossman, M. (Dept. of Neurology. Penn Frontotemporal Degeneration Center. University of Pennsylvania Perelman School of Medicine) ;
Irwin, D. (Dept. of Neurology. Penn Frontotemporal Degeneration Center. University of Pennsylvania Perelman School of Medicine) ;
Sanchez-Valle, R. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Graff, Caroline (Unit of Hereditary Dementia. Theme Aging. Karolinska University Hospital-Solna) ;
Vandenberghe, R. (Laboratory for Cognitive Neurology. Department of Neurosciences. Leuven Brain Institute) ;
Pijnenburg, Y.A.L. (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Vrije Universiteit Amsterdam) ;
Laforce, R. (Clinique Interdisciplinaire de Mémoire du CHU de Québec. département des Sciences Neurologiques. Université Laval) ;
Ber, I.L. (Sorbonne Université. Paris Brain Institute. Institut du Cerveau. ICM. Inserm U1127. CNRS UMR 7225. APHP. Hôpital Pitié-Salpêtrière) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Haass, Christian (Munich Cluster for Systems Neurology (SyNergy)) ;
Suarez-Calvet, M. (German Center for Neurodegenerative Diseases (DZNE) Munich) ;
van Swieten, J.C. (Alzheimer Center Rotterdam and Dept. of Neurology. Erasmus University Medical Center) ;
Seelaar, H. (Alzheimer Center Rotterdam and Dept. of Neurology. Erasmus University Medical Center)
Excessive microglial activation might be a central pathological process in GRN-related frontotemporal dementia (FTD-GRN). We measured soluble triggering receptor expressed on myeloid cells 2 (sTREM2), which is shed from disease-associated microglia following cleavage of TREM2, in cerebrospinal fluid of 34 presymptomatic and 35 symptomatic GRN mutation carriers, 6 presymptomatic and 32 symptomatic C9orf72 mutation carriers and 67 healthy noncarriers by ELISA. [...]
2021 - 10.1016/j.neurobiolaging.2021.02.024
Neurobiology of Aging, Vol. 103 (july 2021) , p. 158.e1-158.e5
|
|
|
5.
|
|
15 p, 220.9 KB |
Importance of cerebrospinal fluid storage conditions for the Alzheimer's disease diagnostics on an automated platform
/
Ferrer, Rosa (Institut d'Investigació Biomèdica Sant Pau) ;
Zhu, Nuole (Institut d'Investigació Biomèdica Sant Pau) ;
Arranz Martínez, Javier (Institut d'Investigació Biomèdica Sant Pau) ;
Porcel, Inmaculada (Institut d'Investigació Biomèdica Sant Pau) ;
El Bounasri, Shaimaa (Institut d'Investigació Biomèdica Sant Pau) ;
Sánchez, Oriol (Institut d'Investigació Biomèdica Sant Pau) ;
Torres, Soraya (Institut d'Investigació Biomèdica Sant Pau) ;
Julve i Gil, Josep (Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Blanco Vaca, Francisco (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Tondo, Mireia (Institut d'Investigació Biomèdica Sant Pau)
Objectives: Alzheimer's disease (AD) is considered the most common cause of dementia in older people. Cerebrospinal fluid (CSF) Aβ1-42, Aβ1-40, total Tau (t-Tau), and phospho Tau (p-Tau) are important biomarkers for the diagnosis, however, they are highly dependent on the pre-analytical conditions. [...]
2022 - 10.1515/cclm-2022-0134
Clinical Chemistry and Laboratory Medicine, Vol. 60 Núm. 7 (2022) , p. 1058-1063
|
|
|
6.
|
|
13 p, 1.8 MB |
Replication study of plasma proteins relating to Alzheimer's pathology
/
Shi, Liu (University of Oxford. Department of Psychiatry) ;
Winchester, Laura M. (University of Oxford. Department of Psychiatry) ;
Westwood, Sarah (University of Oxford. Department of Psychiatry) ;
Baird, Alison L (University of Oxford. Department of Psychiatry) ;
Anand, Sneha N (University of Oxford. Department of Psychiatry) ;
Buckley, Noel J. (University of Oxford. Department of Psychiatry) ;
Hye, Abdul (Maurice Wohl Clinical Neuroscience. Institute of Psychiatry. Psychology and Neuroscience. Kings College London) ;
Ashton, Nicholas J. (University of Gothenburg) ;
Bos, Isabelle (Alzheimer Center. VU University Medical Center) ;
Vos, Stephanie J.B. (Department of Psychiatry and Neuropsychology. School for Mental Health and Neuroscience. Alzheimer Centrum Limburg. Maastricht University) ;
Kate, Mara Ten (Amsterdam UMC. University Medical Center) ;
Scheltens, Philip (Amsterdam UMC. University Medical Center) ;
Teunissen, Charlotte E. (Amsterdam University Medical Centers (AUMC)) ;
Vandenberghe, Rik (University Hospitals Leuven (Bèlgica)) ;
Gabel, Silvy (KU Leuven. Laboratory for Cognitive Neurology) ;
Meersmans, Karen (KU Leuven. Laboratory for Cognitive Neurology) ;
Engelborghs, Sebastiaan (Department of Neurology. UZ Brussel and Center for Neurociences (C4N). Vrije Universiteit Brussel) ;
De Roeck, Ellen E (Department of Neurology and Memory Clinic. Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken) ;
Sleegers, Kristel (University of Antwerp. Institute Born-Bunge) ;
Frisoni, Giovanni B. (IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli) ;
Blin, Olivier (AIX marseille university. INS. Ap-hm) ;
Richardson, Jill C. (Neurosciences Therapeutic Area. GlaxoSmithKline R&D) ;
Bordet, Régis (Inserm. University of Lille. CHU Lille) ;
Molinuevo, José L. (Barcelonaβeta Brain Research Center (BBRC)) ;
Rami Gonzalez, Lorena (Barcelonaβeta Brain Research Center (BBRC)) ;
Wallin, Anders (Institute of Neuroscience and Physiology. Sahlgrenska Academy at University of Gothenburg) ;
Kettunen, Petronella (Institute of Neuroscience and Physiology. Sahlgrenska Academy at University of Gothenburg) ;
Tsolaki, Magda (AHEPA University Hospital (Grècia)) ;
Verhey, Frans (Department of Psychiatry and Neuropsychology. School for Mental Health and Neuroscience. Alzheimer Centrum Limburg. Maastricht University) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Sala, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Popp, Julius (Geriatric Psychiatry. Department of Mental Health and Psychiatry. Geneva University Hospitals) ;
Peyratout, Gwendoline (Lausanne University Hospital) ;
Martinez-Lage, Pablo (CITA-Alzheimer Foundation) ;
Tainta, Mikel (CITA-Alzheimer Foundation) ;
Johannsen, Peter (Danish Dementia Research Centre. Rigshospitalet. Copenhagen University Hospital) ;
Freund-Levi, Yvonne (Karolinska Institutet Center for Alzheimer Research. Division of Clinical Geriatrics. School of Medical Sciences Örebro University and Department of Neurobiology. Caring Sciences and Society (NVS)) ;
Frölich, Lutz (Department of Geriatric Psychiatry. Zentralinstitut für Seelische Gesundheit. University of Heidelberg) ;
Dobricic, Valerija (Lübeck Interdisciplinary Platform for Genome Analytics. Institutes of Neurogenetics and Cardiogenetics. University of Lübeck) ;
Legido-Quigley, Cristina (The Systems Medicine Group. Steno Diabetes Center) ;
Barkhof, Frederik (UCL Institutes of Neurology and Healthcare Engineering) ;
Andreasson, Ulf (Clinical Sahlgrenska University Hospital) ;
Blennow, Kaj (Sahlgrenska University Hospital (Suècia)) ;
Zetterberg, Henrik (UCL Institute of Neurology (Regne Unit)) ;
Streffer, Johannes (UCB. Braine-l'Alleud. Belgium. formerly Janssen R&D. LLC Beerse) ;
Lill, Christina M. (Ageing Epidemiology Research Unit. School of Public Health. Imperial College) ;
Bertram, Lars (Department of Psychology. University of Oslo) ;
Visser, Pieter Jelle (Alzheimer Center. VU University Medical Center) ;
Kolb, Hartmuth C. (Janssen R&D) ;
Narayan, Vaibhav A. (Janssen R&D) ;
Lovestone, Simon (Janssen R&D) ;
Nevado-Holgado, Alejo (Department of Psychiatry. University of Oxford)
Introduction: This study sought to discover and replicate plasma proteomic biomarkers relating to Alzheimer's disease (AD) including both the "ATN" (amyloid/tau/neurodegeneration) diagnostic framework and clinical diagnosis. [...]
2021 - 10.1002/alz.12322
Alzheimer's & Dementia, Vol. 17 Núm. 9 (september 2021) , p. 1452-1464
|
|
|
7.
|
|
10 p, 855.6 KB |
Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy
/
De Kort, A.M. (Department of Neurology. Radboud University Medical Center. Donders Institute for Brain. Cognition and Behaviour. Radboud Alzheimer Centre) ;
Kuiperij, H.B. (Department of Neurology. Radboud University Medical Center. Donders Institute for Brain. Cognition and Behaviour. Radboud Alzheimer Centre) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Kersten, I. (Department of Neurology. Radboud University Medical Center. Donders Institute for Brain. Cognition and Behaviour. Radboud Alzheimer Centre) ;
Versleijen, A.A.M. (Department of Laboratory Medicine. Radboud University Medical Center) ;
Greenberg, S.M. (Massachusetts General Hospital (Boston)) ;
Stoops, E. (ADx NeuroSciences) ;
Schreuder, F.H.B.M. (Department of Neurology. Radboud University Medical Center. Donders Institute for Brain. Cognition and Behaviour. Radboud Alzheimer Centre) ;
Klijn, C.J.M. (Department of Neurology. Radboud University Medical Center. Donders Institute for Brain. Cognition and Behaviour. Radboud Alzheimer Centre) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Claassen, Jurgen A. H. R (Department of Geriatrics. Radboud University Medical Center. Donders Institute for Brain. Cognition and Behaviour. Radboud Alzheimer Centre) ;
Verbeek, M.M. (Department of Laboratory Medicine. Radboud University Medical Center) ;
Universitat Autònoma de Barcelona
Background: Neuroleukin (NLK) is a protein with neurotrophic properties and is present in a proportion of senile plaques and amyloid laden vessels. It has been suggested that NLK is part of a neuroprotective response to amyloid β-induced cell death. [...]
2021 - 10.1186/s13195-021-00899-0
Alzheimer's research & therapy, Vol. 13 Núm. 1 (december 2021) , p. 160
|
|
|
8.
|
|
13 p, 2.5 MB |
TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels
/
Hong, Shengjun (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA). University of Lübeck) ;
Dobricic, Valerija (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA). University of Lübeck) ;
Ohlei, Olena (Lübeck Interdisciplinary Platform for Genome Analytics (LIGA). University of Lübeck) ;
Bos, Isabelle (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Vrije Universiteit Amsterdam) ;
Vos, Stephanie J.B. (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Vrije Universiteit Amsterdam) ;
Prokopenko, Dimitry (Massachusetts General Hospital (Boston)) ;
Tijms, Betty M. (Vrije Universiteit Amsterdam) ;
Andreasson, Ulf (Sahlgrenska University Hospital (Suècia)) ;
Blennow, Kaj (Sahlgrenska University Hospital (Suècia)) ;
Vandenberghe, Rik (University Hospitals Leuven (Bèlgica)) ;
Gabel, Silvy (KU Leuven. Department of Neurosciences) ;
Scheltens, Philip (Vrije Universiteit Amsterdam) ;
Teunissen, Charlotte E. (Amsterdam University Medical Centers (AUMC)) ;
Engelborghs, Sebastiaan (Vrije Universiteit Brussel) ;
Frisoni, Giovani (IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli) ;
Blin, Olivier (AIX Marseille University. INS. Ap-hm) ;
Richardson, Jill C. (Neurosciences Therapeutic Area. GlaxoSmithKline R&D) ;
Bordet, Régis (Inserm. CHU Lille. University of Lille) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Popp, Julius (Lausanne University Hospital) ;
Clark, Christopher (University Hospital of Psychiatry Zurich) ;
Peyratout, Gwendoline (University Hospital of Lausanne. Department of Psychiatry) ;
Martinez-Lage, Pablo (Department of Neurology. Center for Research and Advanced Therapies. CITA-Alzheimer Foundation) ;
Tainta, Mikel (Department of Neurology. Center for Research and Advanced Therapies. CITA-Alzheimer Foundation) ;
Dobson, Richard J.B. (University College London. Hospitals Biomedical Research Centre) ;
Legido-Quigley, Cristina (King's College London) ;
Sleegers, Kristel (University of Antwerp. Institute Born-Bunge) ;
Van Broeckhoven, Christine (University of Antwerp) ;
Tanzi, Rudolph E. (Genetics and Aging Unit and McCance Center for Brain Health. Department of Neurology. Massachusetts General Hospital) ;
ten Kate, Mara (Amsterdam UMC. University Medical Center) ;
Wittig, Michael (Christian-Albrechts-University of Kiel. Institute of Clinical Molecular Biology) ;
Franke, Andre (Christian-Albrechts-University of Kiel. Institute of Clinical Molecular Biology) ;
Lill, Christina M. (Imperial College. School of Public Health) ;
Barkhof, Frederik (University College London. Institutes of Neurology and Healthcare Engineering) ;
Lovestone, Simon (University of Oxford. Department of Psychiatry) ;
Streffer, Johannes (Translational Medicine Neuroscience. UCB Biopharma SPRL. Braine l'Alleud) ;
Zetterberg, Henrik (UCL Institute of Neurology (Regne Unit). UK Dementia Research Institute) ;
Visser, Pieter J. (Karolinska Instutet. Department of Neurobiology) ;
Bertram, Lars (University of Oslo. Department of Psychology)
Introduction: Neurofilament light (NfL), chitinase-3-like protein 1 (YKL-40), and neurogranin (Ng) are biomarkers for Alzheimer's disease (AD) to monitor axonal damage, astroglial activation, and synaptic degeneration, respectively. [...]
2021 - 10.1002/alz.12330
Alzheimer's & Dementia, Vol. 17 Núm. 10 (october 2021) , p. 1628-1640
|
|
|
9.
|
|
11 p, 1.6 MB |
Association of Apolipoprotein e ϵ4 Allele with Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults with down Syndrome
/
Bejanin, Alexandre (Institut d'Investigació Biomèdica Sant Pau) ;
Iulita, M. Florencia (Institut d'Investigació Biomèdica Sant Pau) ;
Vilaplana, Eduard (Institut d'Investigació Biomèdica Sant Pau) ;
Carmona Iragui, María (Institut d'Investigació Biomèdica Sant Pau) ;
Benejam, Bessy (Barcelona Down Medical Center. Fundació Catalana Síndrome de Down) ;
Videla Toro, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Barroeta, Isabel (Institut d'Investigació Biomèdica Sant Pau) ;
Fernandez, S. (Universitat Autònoma de Barcelona) ;
Altuna-Azkargorta, Miren (Institut d'Investigació Biomèdica Sant Pau) ;
Pegueroles, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Montal, Victor (Institut d'Investigació Biomèdica Sant Pau) ;
Valldeneu, Silvia (Institut d'Investigació Biomèdica Sant Pau) ;
Giménez, Sandra (Institut d'Investigació Biomèdica Sant Pau) ;
González-Ortiz, Sofía (Hospital del Mar (Barcelona, Catalunya)) ;
Muñoz, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Padilla, Concepción (Institut d'Investigació Biomèdica Sant Pau) ;
Aranha, Mateus (Institut d'Investigació Biomèdica Sant Pau) ;
Estellés, T. (Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED)) ;
Illán-Gala, Ignacio (Institut d'Investigació Biomèdica Sant Pau) ;
Belbin, Olivia (Institut d'Investigació Biomèdica Sant Pau) ;
Camacho, Valle (Institut d'Investigació Biomèdica Sant Pau) ;
Wilson, L.R. (Cambridge Intellectual and Developmental Disabilities Research Group. Department of Psychiatry. University of Cambridge. Douglas House) ;
Annus, Tiina (Cambridge Intellectual and Developmental Disabilities Research Group. Department of Psychiatry. University of Cambridge. Douglas House) ;
Osorio, R.S. (Healthy Brain Aging and Sleep Center. Department of Psychiatry. New York University. Grossman School of Medicine) ;
Videla, S. (Institut d'Investigació Biomèdica de Bellvitge) ;
Lehmann, S. (Le Laboratoire de Biochimie et Protéomique Clinique. Université Montpellier. Centre Hospitalier Universitaire Montpellier. Institut National de la Santé et de la Recherche Médicale) ;
Holland, Anthony (Cambridge Intellectual and Developmental Disabilities Research Group. Department of Psychiatry. University of Cambridge. Douglas House) ;
Zetterberg, Henrik (Department of Neurodegenerative Disease. UCL Queen Square Institute of Neurology) ;
Blennow, Kaj (Sahlgrenska University Hospital (Suècia)) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Clarimón, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Zaman, S.H. (Cambridgeshire and Peterborough National Health Service (NHS) Foundation Trust. Fulbourn Hospital. Elizabeth House) ;
Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Importance: Alzheimer disease (AD) is the leading cause of death in individuals with Down syndrome (DS). Previous studies have suggested that the APOE ϵ4 allele plays a role in the risk and age at onset of dementia in DS; however, data on in vivo biomarkers remain scarce. [...]
2021 - 10.1001/jamaneurol.2021.1893
JAMA Neurology, Vol. 78 Núm. 8 (august 2021) , p. 937-947
|
|
|
10.
|
|
10 p, 392.2 KB |
Neuroinflammation-Related Proteins NOD2 and Spp1 Are Abnormally Upregulated in Amyotrophic Lateral Sclerosis
/
de Luna Salva, Noemí (Institut d'Investigació Biomèdica Sant Pau) ;
Carbayo, Álvaro (Institut d'Investigació Biomèdica Sant Pau) ;
Dols Icardo, Oriol (Institut d'Investigació Biomèdica Sant Pau) ;
Turon-Sans, Janina (Institut d'Investigació Biomèdica Sant Pau) ;
Reyes-Leiva, David (Institut d'Investigació Biomèdica Sant Pau) ;
Illán-Gala, Ignacio (Institut d'Investigació Biomèdica Sant Pau) ;
Jericó, Ivonne (Institut d'Investigació Biomèdica Sant Pau) ;
Pagola-Lorz, Inma (Institut d'Investigació Biomèdica Sant Pau) ;
Lleixà, Cinta (Institut d'Investigació Biomèdica Sant Pau) ;
Querol, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Rubio-Guerra, Sara (Institut d'Investigació Biomèdica Sant Pau) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Cortés-Vicente, Elena (Institut d'Investigació Biomèdica Sant Pau) ;
Rojas-Garcia, Ricardo (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of unknown etiology and poorly understood pathophysiology. There is no specific biomarker either for diagnosis or prognosis. The aim of our study was to investigate differentially expressed proteins in the CSF and serum from patients with ALS to determine their role in the disease process and evaluate their utility as diagnostic or prognostic biomarkers. [...]
2022 - 10.1212/NXI.0000000000200072
Neurology® neuroimmunology & neuroinflammation, Vol. 10 (december 2022)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
